SK150297A3 - Alpha-substituted pyrimidine-thioalkyl and alkylether compounds as inhibitors of viral reverse transcriptase - Google Patents

Alpha-substituted pyrimidine-thioalkyl and alkylether compounds as inhibitors of viral reverse transcriptase Download PDF

Info

Publication number
SK150297A3
SK150297A3 SK1502-97A SK150297A SK150297A3 SK 150297 A3 SK150297 A3 SK 150297A3 SK 150297 A SK150297 A SK 150297A SK 150297 A3 SK150297 A3 SK 150297A3
Authority
SK
Slovakia
Prior art keywords
dihydro
pyridinyl
amino
chloro
compound
Prior art date
Application number
SK1502-97A
Other languages
English (en)
Slovak (sk)
Inventor
Richard A Nugent
Donn G Wishka
Gary J Cleek
David R Graber
Stephen T Schlachter
Michael J Murphy
Joel Morris
Richard C Thomas
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of SK150297A3 publication Critical patent/SK150297A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
SK1502-97A 1995-05-08 1996-05-03 Alpha-substituted pyrimidine-thioalkyl and alkylether compounds as inhibitors of viral reverse transcriptase SK150297A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43670895A 1995-05-08 1995-05-08
PCT/US1996/006119 WO1996035678A1 (en) 1995-05-08 1996-05-03 Alpha-substituted pyrimidine-thioalkyl and alkylether compounds as inhibitors of viral reverse transcriptase

Publications (1)

Publication Number Publication Date
SK150297A3 true SK150297A3 (en) 1998-10-07

Family

ID=23733510

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1502-97A SK150297A3 (en) 1995-05-08 1996-05-03 Alpha-substituted pyrimidine-thioalkyl and alkylether compounds as inhibitors of viral reverse transcriptase

Country Status (27)

Country Link
US (1) US6043248A (xx)
EP (2) EP1449835A3 (xx)
JP (1) JPH11507017A (xx)
KR (1) KR100445498B1 (xx)
CN (2) CN1152022C (xx)
AT (1) ATE275550T1 (xx)
AU (1) AU712404B2 (xx)
BR (1) BR9608265A (xx)
CA (1) CA2216099C (xx)
CZ (1) CZ293135B6 (xx)
DE (1) DE69633332T2 (xx)
ES (1) ES2227586T3 (xx)
GE (1) GEP20002297B (xx)
HK (1) HK1009446A1 (xx)
HU (1) HUP9801995A3 (xx)
IL (1) IL118075A0 (xx)
MX (1) MX9708582A (xx)
NO (1) NO310287B1 (xx)
NZ (1) NZ307089A (xx)
PL (1) PL323240A1 (xx)
PT (1) PT824524E (xx)
RU (1) RU2167155C2 (xx)
SK (1) SK150297A3 (xx)
TW (1) TW450962B (xx)
UA (1) UA56992C2 (xx)
WO (1) WO1996035678A1 (xx)
ZA (1) ZA963281B (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1309656A (zh) * 1997-09-25 2001-08-22 法玛西雅厄普约翰美国公司 烷硫基α－取代的嘧啶化合物
US6111111A (en) * 1997-10-23 2000-08-29 Kuraray Co., Ltd. Intermediates for producing pyridine derivatives
EP1121129B1 (en) 1998-09-17 2008-09-03 Bristol-Myers Squibb Company METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND ASSOCIATED COMBINATIONS
US7358254B2 (en) 2001-07-13 2008-04-15 Bristol-Myers Squibb Company Method for treating atherosclerosis employing an aP2 inhibitor and combination
ATE253915T1 (de) 1999-06-30 2003-11-15 Merck & Co Inc Src-kinase hemmende verbindungen
AU6605200A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
JP2003503354A (ja) 1999-06-30 2003-01-28 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害剤化合物
US7138404B2 (en) * 2001-05-23 2006-11-21 Hoffmann-La Roche Inc. 4-aminopyrimidine derivatives
US7923056B2 (en) 2007-06-01 2011-04-12 Illinois Tool Works Inc. Method and apparatus for dispensing material on a substrate
CA2762680C (en) 2009-05-21 2018-04-17 Chlorion Pharma, Inc. Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
CN101638391B (zh) * 2009-08-21 2011-04-27 山东大学 2-[(取代苯氨基)羰基甲硫基]-6-(2,6-二氯苄基)-3h-嘧啶-4-酮类衍生物及其制备方法与应用
WO2011103559A1 (en) 2010-02-22 2011-08-25 Nektar Therapeutics Oligomer modified diaromatic substituted compounds
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
AP2013006706A0 (en) * 2010-07-02 2013-02-28 Gilead Sciences Inc Napht-2-ylacetic acid derivatives to treat AIDS
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
KR101360587B1 (ko) * 2012-11-01 2014-03-10 현대자동차주식회사 스마트 도어 언록 시스템
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
GB201807898D0 (en) * 2018-05-15 2018-06-27 Kancera Ab New processes and products with increased chiral purity
US20230112484A1 (en) * 2020-01-20 2023-04-13 Agrematch Ltd. Compositions for crop protection
CN114057707A (zh) * 2021-11-24 2022-02-18 上海应用技术大学 一种n-4-吲哚基-2-呋喃甲酰胺化合物的制备方法
WO2023137041A1 (en) * 2022-01-12 2023-07-20 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2295560A (en) * 1941-06-18 1942-09-15 Gen Electric Pyrimidine derivatives
GB744867A (en) * 1952-10-29 1956-02-15 American Cyanamid Co Improvements relating to 2-substituted-mercapto-4-amino-6-disubstituted-aminopyrimidines and acid addition salts thereof
US3940394A (en) * 1972-03-31 1976-02-24 Santilli Arthur A 2-pyrimidinylthio)alkanoic acids, esters, amides and hydrazides
ATE25255T1 (de) * 1983-05-05 1987-02-15 Heumann Ludwig & Co Gmbh Pyrimidin-thioalkylpyridin-derivate, verfahren zu ihrer herstellung und diese verbindung enthaltende arzneimittel.
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
JPS62209062A (ja) * 1986-03-10 1987-09-14 Yamanouchi Pharmaceut Co Ltd ２−ピリジルメチルチオ−または２−ピリジルメチルスルフイニル−置換縮合環化合物
JPH07107056B2 (ja) * 1987-01-30 1995-11-15 日清製粉株式会社 ４（３ｈ）−キナゾリノン誘導体、その製造方法およびそれを有効成分とする抗潰瘍剤
AU3752589A (en) * 1988-05-16 1989-12-12 Georgia State University Research Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
HU203736B (en) * 1989-04-06 1991-09-30 Gyogyszerkutato Intezet Process for producing new thiouracil-derivatives and pharmaceutical compositions containing them
MX9203454A (es) * 1989-12-28 1992-08-01 Upjohn Co Compuestos anti sida diaromaticos substituidos.
US5668136A (en) * 1990-09-25 1997-09-16 Eisai Co., Ltd. Trisubstituted benzene derivatives, composition and methods of treatment
AU653855B2 (en) * 1991-07-03 1994-10-13 Pharmacia & Upjohn Company Indolyl carbonyl pyridinyl-poperazine/piperidine derivatives
GB2266716A (en) * 1992-05-05 1993-11-10 Merck & Co Inc Inhibitors of HIV reverse transcriptase
JP3077046B2 (ja) * 1992-08-31 2000-08-14 久光製薬株式会社 新規なキナゾリン誘導体
CA2168757A1 (en) * 1993-09-17 1995-03-23 Robert A. Chrusciel Substituted tetronic acids useful for treating hiv and other retroviruses
JPH09505050A (ja) * 1993-11-12 1997-05-20 ジ・アップジョン・カンパニー ピリミジン−チオアルキルおよびアルキルエーテル化合物
WO1995029897A1 (en) * 1994-04-29 1995-11-09 G.D. Searle & Co. METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS
CA2195444A1 (en) * 1994-07-20 1996-02-01 Bernhard Kohl Thiopyridyl compounds for controlling helicobacter bacteria

Also Published As

Publication number Publication date
EP1449835A2 (en) 2004-08-25
MX9708582A (es) 1998-02-28
KR19990008400A (ko) 1999-01-25
CA2216099C (en) 2005-09-13
ES2227586T3 (es) 2005-04-01
RU2167155C2 (ru) 2001-05-20
EP1449835A3 (en) 2004-09-15
EP0824524B1 (en) 2004-09-08
NO310287B1 (no) 2001-06-18
EP0824524A1 (en) 1998-02-25
NO975129L (no) 1998-01-07
CA2216099A1 (en) 1996-11-14
ATE275550T1 (de) 2004-09-15
CZ349197A3 (cs) 1998-04-15
CN1535958A (zh) 2004-10-13
DE69633332D1 (de) 2004-10-14
CN1152022C (zh) 2004-06-02
NO975129D0 (no) 1997-11-07
JPH11507017A (ja) 1999-06-22
UA56992C2 (uk) 2003-06-16
AU712404B2 (en) 1999-11-04
KR100445498B1 (ko) 2004-11-16
PL323240A1 (en) 1998-03-16
CZ293135B6 (cs) 2004-02-18
CN1183773A (zh) 1998-06-03
HK1009446A1 (en) 1999-09-10
GEP20002297B (en) 2000-11-25
IL118075A0 (en) 1996-08-04
AU5635396A (en) 1996-11-29
HUP9801995A3 (en) 1999-04-28
HUP9801995A2 (hu) 1999-03-29
PT824524E (pt) 2005-01-31
DE69633332T2 (de) 2005-09-22
ZA963281B (en) 1997-10-24
NZ307089A (en) 1999-07-29
US6043248A (en) 2000-03-28
TW450962B (en) 2001-08-21
WO1996035678A1 (en) 1996-11-14
BR9608265A (pt) 1999-02-02

Similar Documents

Publication Publication Date Title
RU2167155C2 (ru) Замещенные пиримидинтиоалкильные или алкилэфирные соединения и способ ингибирования обратной транскриптазы вирусов
JP3398152B2 (ja) １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体
JP2896532B2 (ja) 新規なピリミジン誘導体およびその製造方法
US5981537A (en) Pyrimidine-thioalkyl and alkylether compounds
CZ20023199A3 (cs) Modulátory receptoru adenosinu
TW200410945A (en) Vanilloid receptor ligands and their use in treatments"
US9115093B2 (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
AU2015202675A1 (en) Heteroaryl compounds and uses thereof
JP2001525794A (ja) アリールピリミジン誘導体
TW202216707A (zh) 胺基嘧啶酮衍生物
US6124306A (en) Thioalkyl alpha substituted pyrimidine compounds
WO2017108203A1 (en) Novel substituted indoline compounds as phosphodiesterase inhibitors
USRE47493E1 (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity